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Abstract
OBJECTIVE: To investigate the molecular effect of
Socheongryong Tang (SCRT, Xiaoqinglong Tang in
Chinese) on whole genome level in asthma mouse
model by microarray technology.
METHODS: Asthma was induced by intranasal in-
stillation of ovalbumin in mouse. After administra-
tion of SCRT on asthma-induced mouse, the expres-
sion of genes in lung tissue was measured using
whole genome microarray. The functional implica-
tion of differentially expressed genes was per-
formed using ontological analysis and the similarity
of promoter structure of genes was also analyzed.
RESULTS: Treatment of SCRT restored expression
level of many up- or down-regulated genes in asth-
ma model, and this recovery rate means SCRT
could regulate a set of genes having specific TFBS
binding sites.
CONCLUSION: In this study, we identified a set of
genes subjected to similar regulation by SCRT in
asthma model in mice.
© 2015 JTCM. All rights reserved.
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INTRODUCTION
Socheongryong Tang (SCRT, Xiaoqinglong Tang in
Chinese; Sho-Seiryu-To in Japanese) is a well-known
traditional herbal medicine for allergic rhinitis, bron-
chitis, bronchial asthma and cold symptoms in Korea.1,2
Recently, SCRT was known to have an anti-allergic ac-
tivity on airway inflammation in a mouse model.3 In
addition, in vitro analysis shows several anti-allergic ac-
tivity of SCRT including inhibition of histamine re-
lease,4,5 proliferation of eosinophils and basophils.6,7 In-
terestingly, SCRT was shown to decrease the expres-
sion of the interleukin (IL)-4 mRNA, which suppresses
Th2 cell development1,2 which have relevance to our
previous report.8 These evidences indicate SCRT
would exert various immuno-suppressive effects in vivo
and in vitro although the molecular mechanism has
not been clearly demonstrated.
Throughout the world, asthma is a serious public
health problem affecting people of all ages, and is an in-
flammatory disease of the airways which may be wors-
ened due to numerous extrinsic factors. The most com-
mon trigger is continuous exposure to allergens.9 Aller-
gic asthma is characterized by reversible airway obstruc-
tion, increased mucus production, infiltration of eosin-
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ophils, and nonspecific airway hyper-responsiveness,
and its development is mediated by the over-expression
of Th2-mediated or Th1-mediated cytokines, includ-
ing IL-4, IL-5, IL-8, and tumor necrosis factor-α.10,11
The pathophysiological mechanism of asthma is still
unclear despite the increasing prevalence of this dis-
ease, and current treatments are not satisfactory.
Severe asthma accounts for only 5% to 10% of pa-
tients with asthma, but it accounts for a considerable
portion of the health care costs associated with this dis-
ease, and patients with severe asthma are particularly
difficult to treat.12-15 Current therapies incompletely
control symptoms of asthma and even intensive treat-
ment having little effect on health care utilization.15
Consequently, effort should be made to identify new
remedies, preferably of natural origin, for mitigating
these disorders. We previously reported the strong pos-
sibility of SCRT as a complementary or alternative
drug to western drug also demonstrated that regulation
of Th1/Th2 imbalance may be one of mechanism con-
tributed to treatment for respiratory disease by SCRT.8
However, it is difficult to elucidate pharmaceutical
mechanism of mixed herbal formula such as SCRT be-
cause of complex nature of herbal components. Recent
development of microarray makes it possible to investi-
gate the effect of chemicals in molecular level. By ap-
plying microarray technology, expression levels of thou-
sands of genes can be measured simultaneously. There-
fore, in this study, the effect of SCRT on asthma mod-
el in mouse was investigated on whole genome level.
MATERIALS ANDMETHODS
Animal
Eight week-old female Balb/c mice (Orient Bio, Sung-
nam, Korea) were housed in polypropylene cages at
(24 ± 3) ℃ under 12 h light and dark cycle for at least
2 weeks prior to the experiment. They were fed with
standard pellet diet and water ad libitum. All experi-
ments were approved by Institutional Animal Care
committee of Seoul National University and conduct-
ed in accordance with the guidelines of Seoul National
University.
Preparation of SCRT
Eight species of dried medicinal herbs composing
SCRT were supplied by H-Max Pharmaceutics Ltd.
(Seoul, Korea), and were authenticated by one of the
authors (SIC, an experienced Pharmacognost) at the
School of Korean Medicine, Pusan National Universi-
ty, where voucher specimens (No. SKM-SCRT-201-
208) were deposited. As shown in Table 1, SCRT was
composed of eight species of medicinal herbs and the
mixture of ingredients was boiled in 1300 mL of dis-
tilled water using Herb Extractor (Dae Woong, Seoul,
Korea) for 3 h to make the final volume of 500 mL.
The extract was centrifuged at 2200 × g for 20 min,
and then it was filtered using Whattman filter paper
No. 3. The filtrate was condensed using Vacuum Evap-
orator (EYELA, Tokyo, Japan) and then stored at
﹣20℃ until use.
Induction of asthma
Twenty one mice were divided into three groups (7 mice
for naive, 7 mice for induction of asthma and 7 mice
for induction of asthma with SCRT administration).
Two weeks after intraperitoneal injection of 100 mL
of phosphate buffer saline (PBS) for naïve or emulsion
containing 100 μg of ovalbumin (OVA) and 2 mg of
alum for induction of asthma for 3 consecutive days
(Days 1-3), mice were anesthetized with intraperito-
neal injection of ketamine (100 mg/kg) and rompun
(10 mg/kg). Mice were then treated with intranasal
instillation of 30 mL of PBS containing 25 μg of
OVA for 2 days (Days 18 and 19). Three days later,
intranasal instillation was conducted again for 2 days
(Days 23 and 24). SCRT was given on the last day
of first intranasal instillation period and continued
for 6 days (Day 19-24). The dose of SCRT was 4
times higher than that for human adults. The dose
was determined after consideration of basal metabolic
rates and body weight as in our previous experi-
ments.8
Herbal name
Rhizoma Pinelliae
Herba Ephedrae
Radix Paeoniae
Fructus Schisandrae
Herba Asari
Rhizoma Zingiberis
Ramulus Cinnamomi
Radix Glycyrrhizae
Standard materials
Homogentistic acid
Ephedrine
Paeoniflorin
Schizandrin
Asarone
6-Gingerol
Cinnamaldehyde
Glycyrrhizic acid
Botanical name
Pinelia ternata
Ephedra sinica
Paeonia lactiflora
Schizandra chinensis
Asarum sieboldii
Zingiber officinale
Cinnamomum cassia
Glycyrrhiza uralensis
Amount (g)
16.86
16.86
16.86
16.86
11.25
11.25
11.25
11.25
Table 1 Eight ingredients and standard materials of SCRT
Notes: the herbal names, standard materials and botanical names referenced the Korean Pharmacopoeia 9th edition published by Korean
FDA. The amounts of individual herbs are modified by Korea Institute of Oriental Medicine. Each dosage corresponds to 11/2-times daily
dosage for adult humans (60 kg). SCRT: Socheongryong Tang; FDA: food and drug administration.
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RNA isolation
After treatment with extracts, mice were sacrificed by
intraperitoneal injection of sodium pentobarbital. The
lung tissues were then surgically resected and immedi-
ately frozen in liquid nitrogen. The total RNA was
then isolated using a Qiagen RNeasy Kit according to
the manufacturer's instructions (Qiagen Korea Ltd.,
Seoul, Korea). RNA quality was then checked using
agarose gel electrophoresis in which the ratio of 28S/
18S RNA was measured to be approximately 1.6.
Microarray experiment
RNA from the 7 mice in each group was pooled prior
to analysis to eliminate individual variability. A micro-
array consisted of approximately 45 000 oligo-spots
(Agilent Technologies Co., Santa Clara, CA, USA).
3DNA array detection system was used for probe prep-
aration and hybridization according to the manufactur-
er's protocol (Genisphere, PA, USA) in which 20 g of
total RNA was used to produce fluorescently labeled
cDNA. Total RNA from normal and vehicle-treated
mice was used as reference. Microarray was then
scanned to obtain image file using a ScanArray scanner
(Perkin-Elmer, Boston, USA).
Data analysis
Primary raw data obtained using IMAGENE 4.0 (Bio-
discovery, Hawthorne, CA, USA) were normalized by
Lowess method.16 Only spots having intensity greater
than 1.4 times to that of the background were selected.
Then, for analysis, we selected only genes having
well-measured ratio in all samples. The expressional ra-
tios were then hierarchically clustered using CLUS-
TER and then visualized using TREEVIEW (M.B.
Eisen, http: //rana.lbl.gov). Ontology analysis was per-
formed using GOSTAT algorithms.17 To identify genes
having similar promoters, TFBS in promoter region of
a gene, which was predicted by TOUCAN18 and CON-
FAC program,19 were converted to matrix format in
which columns correspond to specific promoters of
genes and rows to the number of presence of individual
TFBS. We used 1000 bp upstream and 500 bp down-
stream of putative transcription start site obtained us-
ing DBTSS20 as promoter sequence of each gene. The
TFBS matrix was then converted to similarity matrix
using Jaccards algorithm as previously reported. 21 The
identification of genes having similar promoters was an-
alyzed by hierarchical clustering of similarity matrix.
RESULTS
Clustering pattern of gene expression
The effects of administration of SCRT on gene expres-
sion in lung tissue of mouse were measured by microar-
ray analysis. Of a total of approximately 45 000 oligo-
spots on the microarray, genes that were up (2 fold)- or
down (0.5 fold)-regulated in either injured lung or
SCRT treated tissue were clustered according to gene
expression levels. Figure 1A shows expression profile
for the effect of SCRT on injured lung tissue. Specifi-
cally, 1438 genes were up-regulated and 806 genes
were down-regulated in asthma-induced lung tissue
(Figure 1B). The effects of SCRT on the expression ra-
tio of these altered genes were depicted on Figure 2. By
treatment of SCRT on mice, 50.1% (721/1438) of
up-regulated genes and 72.5% (584/806) of down-reg-
ulated genes were restored to normal level. In addition,
it was measured that many genes were newly up- or
down-regulated by SCRT treatment (Figure 1C).
Ontological analysis
Because the recovery rates of altered genes by SCRT-
treatment in injured lung were different between up-
and down-regulated genes, we measured the functional
differences of these genes by analyzing gene ontology.
Table 2 indicates that recovered genes from up-regula-
tion in injured lung would be mainly involved with
metabolic process. Whereas recovered genes from
down-regulation in injured lung was implicated with
various biological processes. The differential functional
distribution between up- and down-regulated genes
means selective recovery of functions by SCRT.
C
A BAsthma
SCRT
﹢ ﹢﹢ ﹣
Asthma
SCRT
﹢ ﹢﹢ ﹣
﹣3 0 3
Figure 1 Expression profiles of altered genes in asthma mod-
el of mice
A: expression pattern of 4390 genes which were altered in
at least one of these experimental conditions was shown in;
B: detailed expression pattern of genes altered only in asth-
ma model of mouse (2275 genes); C: genes altered only in
SCRT administrated mice (1921 genes). Columns represent
experimental condition and rows represent genes. Red and
green indicates up- and down-regulation, respectively.
Scale bar represents the color intensity corresponding to
the expression ratio (logarithm of base 2). SCRT: Socheon-
gryong Tang.
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Promoter analysis
To identify genes that would be regulated by com-
mon signalling pathway, promoter regions of altered
genes in injured lung tissue were analyzed. One thou-
sand base pairs upstream and 500 bp downstream of
transcription start site were used as promoter region
of each gene. We used TOUCAN and CONFAC
program to identify putative transcription factor bind-
ing site (TFBS) in promoter region. The positions of
TFBS for some selected genes were shown in Figure
3. After identification of putative TFBS by CON-
FAC algorithm, the similarity matrix for TFBS
among genes were generated and hierarchically clus-
tered. Promoter regions of initial 553 up-regulated
genes and 232 down-regulated genes in injured lung
were analyzed. The total numbers of TFBS in matrix
were 269 and 268 for up- and down-regulated genes,
respectively. The similarity profile of these genes on
TFBS was shown in Figure 4. In both cases of up-
and down-regulated genes in asthma mice model, we
could identify correlated cluster of genes clearly. The
cluster includes 120 up-regulated genes and 47
down-regulated genes. The top 10 list of these genes
were depicted in Table 3. The recovery rates of these
genes having similar TFBS were 66.7% and 85.1%
for up- and down-regulated genes, respectively, in
asthma model in mice (Figure 5). When compared
with recovery rate obtained using all altered genes
(50.1% and 72.5% for up and down-regulation,
each), significant increase of recovery rate was mea-
sured, that is, 66.7% and 85.1% for up- and down-
regulated genes, respectively.
Function
Biological
Process
Molecular
Function
Cellular
Component
Recovered from up-regulation
GO ID
0044260
0019538
0044267
0043170
0016192
0005515
0003735
0008565
0004842
0003723
0005622
0005737
0044424
0043226
0043229
P value
2.23e-06
2.23e-06
2.32e-06
2.66e-05
3.07e-05
0.00604
0.0149
0.0195
0.0314
0.0466
8.4e-11
8.4e-11
1.17e-10
6.83e-05
7.85e-05
Function
Cellular macromolecule metabolic process
Protein metabolic process
Cellular protein metabolic process
Macromolecule metabolic process
Vesicle-mediated transport
Protein binding
Structural constituent of ribosome
Protein transporter activity
Ubiquitin-protein ligase activity
RNA binding
Intracellular
Cytoplasm
Intracellular part
Organelle
Intracellular organelle
Recovered from down-regulation
GO ID
0021543
0007242
0050715
0021987
0051179
0030695
0004373
0005432
0004143
0008066
0008021
0030135
0014069
0031988
0031982
P value
0.139
0.139
0.139
0.139
0.139
0.109
0.112
0.191
0.191
0.191
0.0294
0.0631
0.1
0.14
0.14
Function
Pallium development
Intracellular signaling cascade
Positive regulation of cytokine
secretion
Cerebral cortex development
Localization
GTPase regulator activity
Glycogen (starch) synthase activity
Calcium: sodium antiporter activity
Diacylglycerol kinase activity
Glutamate receptor activity
Synaptic vesicle
Coated vesicle
Postsynaptic density
Membrane-bounded vesicle
Vesicle
Notes: GO ID represents the identification number determined by Gene ontology. The P value was calculated by Chi square or Fisher's ex-
act test based on the total array element. For correction of multiple testing, false discovery rate using Benjamini and Hochlberg method
was applied. SCRT: Socheongryong Tang.
Table 2 Ontological analysis of restored genes by SCRT administration
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Figure 2 Effect of administration of SCRT on the expression of genes altered in asthma model of mice
A: up-regulated genes; B: down-regulated genes. The figures represent the number of up-regulated and down-regulated genes
according to each treatment condition. The dotted line indicates the baseline of up- or down-regulation. Core node genes were
determined as genes showing interaction edges with at least 10 neighborhood nodes. SCRT: Socheongryong Tang.
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DISCUSSION
Although SCRT has been traditionally used to treat al-
lergic disease such as allergic rhinitis, bronchitis, and
bronchial asthma in Asian traditional medicine,1,22 the
mechanism of pharmaceutical effect has not been clear-
ly reported yet. In recent, in vivo and in vitro studies
showed anti-allergic activity of SCRT in which many
kinds of immune cells and cytokines is regulated by
treatment of SCRT.2,3,7,23,24 In this study, we analyzed
the effect of SCRT on asthma model in mice. As
shown in Figure 1 and 2, expression level of many up-
or down-regulated genes in asthma model is restored
by treatment of SCRT. Whereas recovered genes from
up-regulation in injured lung are mainly implicated
with metabolic process, recovered genes from down-
regulation is implicated with various functions such as
pallium development, signaling cascade and regulation
of cytokine secretion. Because the recovered genes by
treatment with SCRT were composed of functionally
different genes, we then tried to refine these recovered
genes based on TFBS similarity. For recovered genes
from up or down-regulation in injured lung, major dis-
tinctive cluster could be discriminated (Figure 4 and
Table 3). When the recovery rate was re-measured with
these genes having similar TFBS binding sites, 66.7%
and 85.1% of recovery rate were obtained from up-
and down-regulation, respectively. Compared to overall
recovery rate obtained using all genes (50.1% and
72.5% for up and down-regulation, respectively), re-
fined recovery rate increased about 16% (for up-regula-
tion) and 13% (for down-regulation) (Figure 5). This
﹣1000 bp
Frs2
Slc15a2
Itpr2
Col8a1
Enpp6
Scyl2
Tmtc2
Dirc2
Kcnj3
Zbtb40
Ttn
Slc7a1
0 500 bp
Up
Down
Figure 3 Promoter regions of some altered genes in asthma model of mouse
TFBS of each gene were predicted using TOUCAN program from 1000 bp upstream and 500 bp downstream region of transcrip-
tion start site. Each color represents individual TFBS. Each six up- and down-regulated genes in asthma model of mouse were in-
vestigated. TFBS: transcription factor binding site.
BA
Figure 4 Similarity matrix of co-expressed genes
A: the similarity in the promoter regions of up-regulated genes; B: the similarity in the promoter regions of down-regulated
genes. A and B was measured using TFBS clustering method. Red color represents high correlation between promoter regions of
two genes while green color represents low correlation with intensity dependent manner. TFBS: transcription factor binding site.
7
120 39
80
1 47
40
3
2
1
0
﹣1
﹣2
﹣3
Over
Down
Asthma Asthma + SCRT Asthma Asthma + SCRT
A B
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o
Figure 5 Effect of administration of SCRT on the expression of putatively co-regulated genes
A: up- regulated genes; B: down-regulated genes. The figures represent the number of up-regulated and down-regulated genes
under each treatment condition. The dotted line indicates the baseline of up- or down-regulation. SCRT: Socheongryong Tang.
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increase of recovery rate means that SCRT could regu-
late a set of genes having specific TFBS binding sites.
Although having similar TFBS sites, these genes were
implicated with diverse biological processes. The func-
tional relationship among these genes should be stud-
ied further in detail.
The increased recovery rate by treatment with SCRT
does not mean the recovery of asthma itself in mice. In
our previous report, the measurement of biochemical
parameters showed that some sorts of cytokines such as
IL-4, IL-5, and IL-17 were significantly reduced or
even restored to normal level by SCRT in asthma mod-
el in mice8 and the same data were obtained in this
study (data not shown). But these recovery rates of bio-
chemical factors also do not reflect the recovery rate of
asthma directly. Therefore, to measure the exact recov-
ery rate of asthma by SCRT, molecular evidence as well
as biochemical parameters should be considered simul-
taneously.
In conclusion, by applying microarray technology, the
effect of SCRT on asthma model in mouse was investi-
gated on whole genome level. We identified a set of
genes subjected to similar regulation by SCRT in asth-
ma model in mice. The recovery rate using these genes
was more improved than using all genes. Therefore, the
functional implication of these genes on asthma should
be studied more in detail.
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